Literature DB >> 17478129

NMR solution structure of the angiostatic peptide anginex.

Monica M Arroyo1, Kevin H Mayo.   

Abstract

Anginex, a designed peptide 33mer, is known to function both as an antiangiogenic and bactericidal agent. Solving the NMR solution structure of the peptide is key to understand better its structure-activity relationships and to design more bioactive peptides and peptide mimetics. However, structure elucidation of anginex has been elusive due to subunit exchange-induced resonance broadening. Here, we found that performing NMR structural studies in a micellar environment abolishes exchange broadening and allows the structure of anginex to be determined. Anginex folds in an amphipathic, three-stranded antiparallel beta-sheet conformation with functionally key hydrophobic residues lying on one face of the beta-sheet and positively charged, mostly lysine residues, lying on the opposite face. Structural comparison is made with a homologous, yet relatively inactive peptide, betapep-28. These results contribute to the design of peptidomimetics of anginex for therapeutic use against angiogenically-related diseases like cancer, as well as infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17478129      PMCID: PMC1986776          DOI: 10.1016/j.bbapap.2007.03.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  27 in total

1.  Anginex, a designed peptide that inhibits angiogenesis.

Authors:  A W Griffioen; D W van der Schaft; A F Barendsz-Janson; A Cox; H A Struijker Boudier; H F Hillen; K H Mayo
Journal:  Biochem J       Date:  2001-03-01       Impact factor: 3.857

Review 2.  Angiogenesis inhibitors: a new class of drugs.

Authors:  Judah Folkman
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

3.  The chemical shift index: a fast and simple method for the assignment of protein secondary structure through NMR spectroscopy.

Authors:  D S Wishart; B D Sykes; F M Richards
Journal:  Biochemistry       Date:  1992-02-18       Impact factor: 3.162

4.  Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy.

Authors:  Victor L J L Thijssen; Ruben Postel; Ricardo J M G E Brandwijk; Ruud P M Dings; Irina Nesmelova; Sietske Satijn; Nicole Verhofstad; Yusaku Nakabeppu; Linda G Baum; Jeroen Bakkers; Kevin H Mayo; Françoise Poirier; Arjan W Griffioen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-16       Impact factor: 11.205

5.  Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene.

Authors:  F Rastinejad; P J Polverini; N P Bouck
Journal:  Cell       Date:  1989-02-10       Impact factor: 41.582

6.  Anti-tumor activity of the novel angiogenesis inhibitor anginex.

Authors:  Ruud P M Dings; Daisy W J van der Schaft; Balazs Hargittai; Judy Haseman; Arjan W Griffioen; Kevin H Mayo
Journal:  Cancer Lett       Date:  2003-05-08       Impact factor: 8.679

Review 7.  Discovery and development of anti-angiogenic peptides: A structural link.

Authors:  Ruud P M Dings; Irina Nesmelova; Arjan W Griffioen; Kevin H Mayo
Journal:  Angiogenesis       Date:  2003       Impact factor: 9.596

8.  Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity.

Authors:  Kevin H Mayo; Ruud P M Dings; Carolee Flader; Irina Nesmelova; Balasz Hargittai; Daisy W J van der Schaft; Loes I van Eijk; Dinesha Walek; Judy Haseman; Thomas R Hoye; Arjan W Griffioen
Journal:  J Biol Chem       Date:  2003-08-28       Impact factor: 5.157

9.  The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin.

Authors:  Ruud P M Dings; Yumi Yokoyama; Sundaram Ramakrishnan; Arjan W Griffioen; Kevin H Mayo
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

10.  Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.

Authors:  M S O'Reilly; L Holmgren; Y Shing; C Chen; R A Rosenthal; M Moses; W S Lane; Y Cao; E H Sage; J Folkman
Journal:  Cell       Date:  1994-10-21       Impact factor: 41.582

View more
  4 in total

1.  Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.

Authors:  Ruud P M Dings; Nigam Kumar; Michelle C Miller; Melissa Loren; Huzaifa Rangwala; Thomas R Hoye; Kevin H Mayo
Journal:  J Pharmacol Exp Ther       Date:  2012-12-11       Impact factor: 4.030

Review 2.  Anti-angiogenic peptides for cancer therapeutics.

Authors:  Elena V Rosca; Jacob E Koskimaki; Corban G Rivera; Niranjan B Pandey; Amir P Tamiz; Aleksander S Popel
Journal:  Curr Pharm Biotechnol       Date:  2011-08       Impact factor: 2.837

3.  Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven.

Authors:  Ruud P M Dings; Emily S Van Laar; Jeremy Webber; Yan Zhang; Robert J Griffin; Stephen J Waters; John R MacDonald; Kevin H Mayo
Journal:  Cancer Lett       Date:  2008-04-01       Impact factor: 8.679

4.  The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins.

Authors:  Emma Salomonsson; Victor L Thijssen; Arjan W Griffioen; Ulf J Nilsson; Hakon Leffler
Journal:  J Biol Chem       Date:  2011-03-03       Impact factor: 5.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.